Myriad Genetics Inc (MYGN)

Health Care · In Vitro & In Vivo Diagnostic Substances

Turbulence: Extreme Sector-strength: 10th pctile elevated vs peers

Myriad Genetics Inc sits in the Extreme turbulence band, around the 10th percentile of Health Care on balance-sheet strength. The lens reads it as elevated vs peers. The underlying figures, all from public filings:

Revenue (TTM) $825M
Net income (TTM) $-366M
Operating margin -47%
FCF margin -1.7%
Altman Z n/a
Piotroski F 4
Beneish M n/a
Interest coverage -36.876

See the full deep-dive in the app →

Figures from public filings (EDGAR). Descriptive, not advice. No targets, no buy or sell. Price and valuation live in the app.

Get the weekly read by email

The Filter covers the macro backdrop and where balance-sheet strength matters, in the same language as the page above. Descriptive only.

No spam, and the list is never sold or shared. Unsubscribe from any issue.